

Xbrane Biopharma AB invites to Annual General Meeting May 4th, 2023

Stockholm, Sweden – Xbrane Biopharma AB (publ) (Nasdaq Stockholm: XBRANE), has the pleasure to invite all its shareholders to attend the Annual General Meeting Thursday May 4th, 2023, 5.30 p.m. in Inghesalen, Widerströmska Huset, floor 2, Karolinska Institute, Tomtebodavägen 18a i Solna.

Following the formal general meeting, the company CEO, Martin Åmark, will give a presentation followed by a Q&A together with Xbranes' chairman of the board, Anders Tullgren.

Refreshments are served from 4.30 p.m.

Right to attend the annual general meeting and notice

Shareholders wishing to attend the annual general meeting must:

i. on the record date, which is Tuesday 25 April 2023, be registered in the share register maintained by Euroclear Sweden AB. Shareholders, whose shares are registered in the name of a nominee, must temporarily register the shares in their own name at Euroclear Sweden AB. Shareholders whose shares are registered in the name of a nominee must, no later than on Tuesday 25 April 2023, via their nominee, temporarily register the shares in their own name in order to be entitled to participate at the general meeting. Voting registration requested by a shareholder in such time that the registration has been made by the relevant nominee no later than on Thursday 27 April 2023 will be considered in preparations of the share register;

ii. notify their participation at the general meeting no later than Friday 28 April 2023. Notice of participation at the general meeting shall be sent by regular mail to Baker & McKenzie Advokatbyrå, Attn: Elsa Sefastsson, Box 180, 101 23 Stockholm, Sweden or by e-mail to elsa.sefastsson@bakermckenzie.com. Upon notification, the shareholder should state their full name, personal identification number or corporate registration number, address and telephone number, and, where applicable, details of representatives, proxy holders and advisors. A shareholder who wishes to be represented by proxy shall issue a written and dated proxy to the proxy holder. If the proxy is issued by a legal entity, a certified copy of the registration certificate or corresponding document ("Registration Certificate") shall be enclosed. The proxy must not be more than one year old, however, the proxy may be older if it is stated that it is valid for a longer term, maximum five years. The proxy in original and the Registration Certificate, if any, must be available at the general meeting and a copy should well before the meeting be sent to the Company by regular mail to Baker & McKenzie Advokatbyrå, Attn: Elsa Sefastsson, Box 180, 101 23 Stockholm, Sweden or by e-mail to elsa.sefastsson@bakermckenzie.com, and should, in order to facilitate the entrance to the general meeting, be at the Company's disposal no later than on 28 April 2023. A proxy form is available for downloading on the Company's website www.xbrane.com.

Contacts

Martin Åmark, CEO
M: +46 76 309 37 77
E: martin.amark@xbrane.com

Anette Lindqvist, CFO/IR
M: +46 76 325 60 90
E: anette.lindqvist@xbrane.com

About Us

Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 53 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci® is granted market authorization approval in Europe and was launched during the first quarter 2023. Xbrane's head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com

Attachments

[Xbrane Biopharma AB invites to Annual General Meeting May 4th, 2023](#)